Drugs / CMS-D017
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07462780 | Mar → Nov 2026 expected | paroxysmal nocturnal hemoglobinuria | Shenzhen Kangzhe Biotechnology Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMS-D017 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07462780 ↗ |
| Route | Oral | “following single and multiple oral administrations” NCT07462780 ↗ |